



For cheerful, healthy and affluent life.

“The project for pursuing infinite possibility develops a new future”

 MEGURO INSTITUTE CO., LTD.

© MEGURO INSTITUTE CO., LTD.



A Message from the President

In 1925, Meguro Institute Co., Ltd was established as the first name of Osaka Experimental Therapy Institute by late Dr. Yozauro Meguro who studied abroad at Institut Pasteur. Thereafter in 1937, the company name was altered to Meguro Institute.

Since the establishment of our company, we have been engaged in research, development and manufacturing of various sorts of products (raw materials) containing pharmaceuticals and others, by utilizing the health-promoting functions of Lactic acid bacteria and Bacillus subtilis (natto) .

In conformity with upgrading standard by our government for manufacturing and development of pharmaceuticals, Kasai factory was constructed in Hyogo prefecture in 1980. The new factory met GMP requirements and expanded the manufacturing capacity. Since then, we have supplied an array of high quality materials for pharmaceuticals and others, by operating two production sites, Kasai and Ikeda.

In 2014, the new plant was constructed in Kasai factory to augment the manufacturing capacity and meet the increasing demand. At the same time, Ikeda factory was closed and the central office was transferred to Chuo-ku, Osaka.

Our core products, Lactic acid bacteria and Bacillus subtilis (natto), are known as probiotics, which confer a benefit on human health by improving the intestinal microbiota. Today, we are working on production and sales of raw materials for ethical drugs, OTC and food supplements, and feed additives based on these probiotic bacteria.

We are also engaged in the entrusted manufacturing of bacteriological preparations of various bacterial species using our corresponding technologies.

Our company is also moving ahead on joint research with various research institutions to expand the application of our products and we will make efforts to serve our customer's needs by our technologies.

Furthermore, keeping our "Footwork" and "Spirit of challenge", we will dedicate to make contribution to medical treatment, prophylaxis and self-care of the 21st century with our products, i. e., pharmaceuticals, food supplements, feed additives, and so on, created by our bioindustrial technologies.

We hope that we can continue to receive your generous support and your esteemed guidance in the future as well.



President and
Representative
Director
Nobuyuki Inoue

Corporate Philosophy and Management Policy

Corporate Philosophy

Based on our steady management policy, we intend to contribute to enhance people's health and welfare through the development, manufacturing and offering of pharmaceuticals, food supplements, feed additives, and things like that.

Prospect


We aim to be a trusted company as a manufacturer of bulk powder products of lactic acid bacteria and Bacillus subtilis (natto).

Management Policy


Expansion of commissioned manufacturing business
 Development of new probiotic products
 Stable supply of high-quality products of lactic acid bacteria and Bacillus subtilis (natto)

The Trends of Sales Growth

Balancing Of Accounts (Year)	sales (Unit:one million yen)	Profit (Unit:one million yen)
2015	979	31
2016	1041	60
2017	956	45
2018	1011	42
2019	903	44



Sales Ratio





Outline / History

OUTLINE

Name:	Meguro Institute Co.,Ltd
Head Office:	2-6-4 Fushimi-machi, Chuo-ku, Osaka 541-0044, Japan Telephone(06)6223-1451 Facsimile(06)6223-1453
Kasai Factory:	318-1 Aza-kotaninoue-otsu, Hanjyo-cho, Kasai-city, Hyogo 675-2101, Japan Telephone(0790)49-2361 Facsimile(0790)49-1329
Capital:	¥35,200,000
Foundation:	May 1925
President:	Nobuyuki Inoue
Employees:	25
Line of work:	Manufacturer,sales, import, and export of medical drugs, diagnostic, food supplement, feed, and feed additives.
Shareholder:	Maruishi Pharmaceutical Co.,Ltd
Major transacting banks:	Sumitomo Mitsui Banking Corporation Osaka-chuo Branch The Minato Bank Ltd, Osaka Branch

HISTORY

Meguro Institute Co., Ltd was established by the late Dr. Yozaburo Meguro who graduated from Osaka prefectural medical school in 1910.

Then he studied under Dr. Kiyoshi Shiga of "National Institute of Infectious Diseases" regarding bacteriology and immunology. After that, Dr. Meguro devoted himself to medical study for 4 years with Dr. Kiyoshi Shiga at the Kitasato Institute, established by Dr. Shibasaburo Kitasato.

Then Dr. Meguro went to Europe to study abroad, he studied under Dr. Bordet of Institut Pasteur in Belgium, and Dr. Ramone of Institut Pasteur in France, respectively.

1925: Osaka Experimental Therapy Institute (Kita-ku, Osaka-shi) founded

1929: Launched "Biogenin", preparation of Lactic acid bacteria.

1931: Launched "Diphtherial Formo-vaccine".

1937: The company name was altered to Meguro Institute from Osaka Experimental Therapy Institute. Launched "Diphtherial Serum".

1945: The facilities of Meguro Institute in Osaka were burnt down by war. Then the institute was relocated to Kohda-cho, Ikeda-shi, Osaka.

1948: Constructed new facilities at Masumi-cho, Ikeda-shi. Simultaneously, the company organization was converted to joint-stock corporation, and the company name was revised to Meguro Institute Co., Ltd.

1950: Launched "Typhus Vaccine".

1952: Resumed the sale of "Biogenin".

1958: Launched "Japanese encephalitis Vaccine".

1968: Launched "Conc-Enteropoly-R", preparation of multidrug-resistant Lactic Acid Bacteria, and "Bionattomin", preparation of Bacillus subtilis (natto) BN. Both preparations were supplied to the manufacturers of gastrointestinal drugs as the raw materials.

1977: Launched "Reversecell", diagnostic kit for detection of HBs Ag in serum.

1980: Kasai Factory complying with GMP was newly established in Kasai-shi, Hyogo-Prefecture. The capacity for production of probiotic preparations and organ extracts (discontinued in later years) was extended.

1997: Turned into a subsidiary of Maruishi Pharmaceutical Co., Ltd.

2003: Expansion of Kasai Factory was completed.

2014: Construction of the new plant was completed in Kasai factory. Ikeda factory was closed and integrated into Kasai factory. The head office was relocated to Chuo-ku, Osaka.

Corporate Officers / Corporate Organization


Corporate Officers

Nobuyuki Inoue	President and Representative Director
Koji Uda	Senior Managing Director
Shinji Tanigaki	Director of Management Division
Satoru Horii	Director of Factory
Katsuhito Inoue	Associate Director
Masahiro Ikeda	Associate Director
Yoshihiro Mukaiyama	Auditor

(As of June, 2020)

Corporate Organization

Board of Directors Committee



(As of June, 2020)



Pharmaceutical Products

BIO-NATTOMIN

BIO-NATTOMIN (*Bacillus subtilis* BN) is used as an active pharmaceutical ingredient.

Activity

- 1) By oral administration, Bio-nattomin regularizes the function of intestines, and whereby promptly ameliorates dyspepsia, diarrhea and constipation.
- 2) Bio-nattomin helps the digestion and absorption of the ingested foods, and contributes to intestinal health.
- 3) Bio-nattomin improves the intestinal microflora balance by inhibiting the growth of noxious bacteria and promoting the growth of beneficial bacteria in the intestinal tract.

CONC-BIOGENIN

CONC-BIOGENIN (*Streptococcus faecalis* BIO) is used as an active pharmaceutical ingredient.

Activity

- 1) By oral administration, Conc-biogenin alleviates intestinal disorders such as diarrhea and constipation, and improves stool consistency.
- 2) Conc-bigenin helps the digestion and absorption of the ingested foods, inhibits the growth of noxious bacteria and improves the intestinal condition.

CONC-ENTEROPOLY-R

CONC-ENTEROPOLY-R (*Streptococcus faecalis* BIO-4R) is used as an active pharmaceutical ingredient.

Activity

- 1) Conc-Enteropoly-R ameliorates various symptoms (such as antibiotic-associated diarrheas) caused by the intestinal dysbiosis associated with the administration of antibiotics or chemotherapeutics.



Food Supplements / Feed Additives

Food Supplements

Bacillus subtilis BN as raw material
Commodity name : Nattokin Powder

Enterococcus faecium BIO as raw material
Commodity name : E faecium BIO Powder

Feed Additives

Bacillus subtilis BN
Commodity name : Growgen 11
(Marketed by Meiji Seika Kaisha, Ltd.)

Enterococcus faecium BIO-4R
Commodity name : Balantol
(Marketed by Kohkin Chemical Co.,Ltd)